Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ TRAUMA — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Stryker logo
SYKTrauma and Extremities — Net Sales
$1.04B+9.5%
OrthoPediatrics logo
KIDSTrauma and deformity — Net revenue
$43.05M+13.7%
CONMED logo
CNMDOrthopedic Surgery — Net Sales
$147.66M+6.8%
Xtant Medical Holdings logo
XTNTProduct — Revenue
$20.88M-28.7%
Stryker logo
SYKOther Orthopedics — Net Sales
$157M+18.0%
Zimmer Biomet Holdings logo
ZBHSET — Revenue
$562.2M+19.5%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's trauma — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's TRAUMA — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported TRAUMA — sales to customers (note 9) of $833M in Q1 2026.
How has Johnson & Johnson's TRAUMA — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's TRAUMA — sales to customers (note 9) increased by 7.9% year-over-year, from $772M to $833M.
What is the long-term trend for Johnson & Johnson's TRAUMA — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's TRAUMA — sales to customers (note 9) has grown at a 2.2% compound annual growth rate (CAGR), from $2.89B to $3.15B.
What does TRAUMA — sales to customers (note 9) mean?
This metric represents the total revenue generated from the sale of medical devices and surgical instruments specifically designed for the treatment of bone fractures and related orthopedic injuries. It reflects the market demand for the company's trauma-focused product portfolio within the broader medical technology segment. Tracking this revenue stream provides insight into the company's competitive position in the orthopedic trauma market.